ArticleInternational immunopharmacology2012
Mechanistic exploration of AhR-mediated host protection against Streptococcus pneumoniae infection.
Article in International immunopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- The role of the AHR in host-pathogen interactions.Nature reviews. Immunology · 2025Review
- Decreased Aryl Hydrocarbon Receptor Gene Expression and Polymorphic Variants Association with Increase COPD Risk.International journal of chronic obstructive pulmonary disease · 2025Article
- Punicalagin as a novel selective aryl hydrocarbon receptor (AhR) modulator upregulates AhR expression through the PDK1/p90RSK/AP-1 pathway to promote the anti-inflammatory response and bactericidal activity of macrophages.Cell communication and signaling : CCS · 2024Article
- Nutrition, gastrointestinal microorganisms and metabolites in mastitis occurrence and control.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2024Review
- Aryl hydrocarbon receptor activation alters immune cell populations in the lung and bone marrow during coronavirus infection.American journal of physiology. Lung cellular and molecular physiology · 2024Article
- Aryl Hydrocarbon Receptor Activation by Benzo[Cells · 2022Article
- Potential role of polycyclic aromatic hydrocarbons in air pollution-induced non-malignant respiratory diseases.Respiratory research · 2020Review
- Transcriptomic Impact of IMA-08401, a Novel AHR Agonist Resembling Laquinimod, on Rat Liver.International journal of molecular sciences · 2019Article
- The Aryl Hydrocarbon Receptor and Tumor Immunity.Frontiers in immunology · 2018Review
- Local Generation of Kynurenines Mediates Inhibition of Neutrophil Chemotaxis by Uropathogenic Escherichia coli.Infection and immunity · 2016Article
- Toward understanding the role of aryl hydrocarbon receptor in the immune system: current progress and future trends.BioMed research international · 2014Review
- New insights into the aryl hydrocarbon receptor as a modulator of host responses to infection.Seminars in immunopathology · 2013Review
- The aryl hydrocarbon receptor: a novel target for immunomodulation in organ transplantation.Transplantation · 2013Review
- 2,3,7,8-tetrachlorodibenzo-p-dioxin slows the progression of experimental cutaneous Leishmaniasis in susceptible BALB/c and SCID mice.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Streptococcus pneumoniae is a primary cause of invasive bacterial infection and pneumonia and is one of the leading causes of death worldwide. In prior studies we showed that pre-treating mice with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a potent agonist of the aryl hydrocarbon receptor (AhR), protects against S. pneumoniae-induced mortality and reduces pulmonary bacterial burden. The current studies were conducted to help elucidate the mechanism for this protective effect, and to characterize the response in the lung during the first 10h following infection. C57Bl/6 mice were treated with TCDD one day prior to intranasal infection with serotype 3 S. pneumoniae. Monitoring of bacteria in the lung airways revealed that bacterial growth was inhibited in the TCDD-treated animals within 10h of infection. To address the mechanism of this rapid protective response, macrophages, neutrophils, and invariant Natural Killer T (iNKT) cells were quantified, and levels of natural antibodies produced by B-1 B cells were evaluated. Functional assays addressed whether AhR activation reduced the capacity of lung epithelial cells to bind bacteria, and whether TCDD treatment enhanced production of antimicrobial agents in the lung or blood. None of the hypothesized mechanisms was able to explain the protective effect. Finally, the exposure paradigm was manipulated to test whether administration of TCDD after instillation of the bacteria was also protective. Results showed that TCDD must be administered in advance of exposure to bacteria, suggesting that the lung environment is rendered inhospitable to the pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.